Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy
10 août 2021 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy
28 janv. 2021 07h00 HE
|
Trevena Inc.
-- Low incidence of respiratory depression observed with OLINVYK (oliceridine) injection regardless of age or body mass index, in exploratory analysis -- CHESTERBROOK, Pa., Jan. 28, 2021 (GLOBE...
Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts
06 janv. 2021 07h00 HE
|
Trevena Inc.
-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa.,...
Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (oliceridine) injection
30 oct. 2020 07h44 HE
|
Trevena Inc.
-- OLINVYK commercial supply on track and available in November Company funded through Q4 2022, including OLINVYK commercialization -- Company to host conference call at 8:30 a.m. ET on Monday,...
Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting
05 oct. 2020 07h00 HE
|
Trevena Inc.
-- Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine -- CHESTERBROOK, Pa., Oct. 05, 2020 ...
Trevena Announces FDA Approval of OLINVYK™ (oliceridine) injection
10 août 2020 06h30 HE
|
Trevena Inc.
OLINVYK is a new chemical entity approved in adults for the management of acute pain severe enough to require an IV opioid analgesic OLINVYK product availability expected in fourth quarter of 2020 ...
Trevena Announces Advancement of Oliceridine Clinical Development in China by Jiangsu Nhwa Pharmaceutical Co.
03 juin 2020 08h02 HE
|
Trevena Inc.
CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports First Quarter 2020 Results
07 mai 2020 07h00 HE
|
Trevena Inc.
Trevena Reports First Quarter 2020 ResultsFDA review of oliceridine NDA ongoing; PDUFA date August 7, 2020 IND filing for novel S1P modulator (TRV045) in 1H 2021; ongoing collaboration with NIH to...
Trevena Announces Publication of Comprehensive Review of Oliceridine Data
23 avr. 2020 07h00 HE
|
Trevena Inc.
Overview of clinical and nonclinical data to date for oliceridine; includes efficacy data in hard- and soft- tissue surgeries, safety / tolerability data in high-risk patients CHESTERBROOK, Pa.,...
Trevena Reports Fourth Quarter and Full Year 2019 Results
12 mars 2020 07h01 HE
|
Trevena Inc.
PDUFA date of August 7, 2020 for IV oliceridine; FDA considers NDA resubmission complete Initiated proof-of-concept studies for acute migraine (TRV250) and opioid use disorder (TRV734) Announces NIH...